| Lonza–General Electric: biologics manufacuturing technology, 201812–2020 supply biologics facility in Guangzhou using KUBio platform by GE Healthcare |
2018-12-10 |
| Alacris–Seedmatch: financial services, 201812– crowdfunding campaign up to €800k via Seedmatch platform |
2018-12-06 |
| Alacris–SEVERAL: investment, 201812– crowdfunding campaign up to €800k via Seedmatch platform |
2018-12-06 |
| Hookipa–Valneva: drug development services, 201812–202111 collab + manufacturing agreem for developm of immunotherapies with Valneva Sweden AB |
2018-12-06 |
| Merck (DE)–Cyclica: drug discovery services, 201812– collab using cloud-based proteome screening platform for small molecule drug development |
2018-12-06 |
| Novartis–Qiagen: molecular companion diagnostics, 201812– collab developm of CDx for alpelisib (BYL719) |
2018-12-06 |
| AC Immune–Hopp Group: investment, 201812 existent investment dievini Hopp owns 27% of AC Immune SA |
2018-12-05 |
| Apogenix–Hopp Group: investment, 201812 existent investment dievini Hopp owns 92% of Apogenix AG |
2018-12-05 |
| Cassiopea–Hopp Group: investment, 201812 existent investment dievini Hopp owns 1% of Cassiopea SpA |
2018-12-05 |
| Cosmo Pharmaceuticals–Hopp Group: investment, 201812 existent investment dievini Hopp owns 5% of Cosmo SpA |
2018-12-05 |
| CureVac–Hopp Group: investment, 201812 existent investment dievini Hopp owns 80% of CureVac AG |
2018-12-05 |
| Heidelberg Pharma–Hopp Group: investment, 201812 existent investment dievini Hopp owns 83% of Heidelberg Pharma AG |
2018-12-05 |
| Immatics–Hopp Group: investment, 201812 existent investment dievini Hopp owns 38% of Immatics GmbH |
2018-12-05 |
| Joimax–Hopp Group: investment, 201812 existent investment dievini Hopp owns 85% of Joimax GmbH |
2018-12-05 |
| Molecular Health–Hopp Group: investment, 201812 existent investment dievini Hopp owns 95% of Molecular Health GmbH |
2018-12-05 |
| Novaliq–Hopp Group: investment, 201812 existent investment dievini Hopp owns 93% of Novaliq GmbH |
2018-12-05 |
| Anagenesis–Alsace (govt): investment, 201812 financing round Series A 1st closing totalling €3m incl existing investor Cap Innov’Est |
2018-12-04 |
| Anagenesis–Boehringer: investment, 201812 financing round Series A 1st closing totalling €3m incl new investor BIVF |
2018-12-04 |
| Anagenesis–SEVERAL: investment, 201812 financing round Series A €3m 1st closing from BIVF + Cap Innov’Est |
2018-12-04 |
| Boehringer–Domain Therapeutics: drug discovery services, 201812– collab + license agreem €na discovery of GPCR-targeting CNS drugs |
2018-12-04 |
| Leo Pharma–Evotec: drug discovery services, 201812– collab €na integrated drug discovery to generate leads against innovative dermatic targets |
2018-12-04 |
| Argenx–JnJ: investment, 201812 investment $200m of 1.767m new shares at €100.02/share representing 4.68% shareholding by JJDC |
2018-12-03 |
| JnJ–Argenx: cusatuzumab, 201812– collab + license agreem ww with Cilag GmbH for up to $1.6b incl $300m upfront cash |
2018-12-03 |
| Dispendix–Cellink: investment, 201812 acquisition €5m of Dispendix GmbH by Cellink AB |
2018-12-01 |
| Resistell–SEVERAL: investment, 201812 seed financing round CHF850k |
2018-12-01 |
| Hookipa–DarwinHealth: personalised medicine, 201811– collab research + license agreem to develop I-O treatments using systems biology |
2018-11-28 |
| Jecure Therapeutics–Roche: investment, 201811 acquisition of Jecure by Genentech from Versant Ventures |
2018-11-27 |
| Spindiag–SEVERAL: investment, 201811 financing round Series A €3m |
2018-11-27 |
| X4 Pharmaceuticals–Arsanis: investment, 201811– reverse merger with former X4 owners to hold 70% + Arsanis to be renamed X4 ANNOUNCED |
2018-11-27 |
| Adrenomed–HBM: investment, 201811 financing round Series D totalling €24m incl new + co-lead investor HBM Healthcare Investments |
2018-11-26 |
| Adrenomed–MC Services: public relations, 201811 service existent by MC Services |
2018-11-26 |
| Adrenomed–SEVERAL: investment, 201811 financing round Series D €24m with new + co-lead investors Wellington + HBM plus existing investors |
2018-11-26 |
| Adrenomed–Wellington Partners: investment, 201811 financing round Series D totalling €24m incl new + co-lead investor Wellington Partners |
2018-11-26 |
| Bayer–Cyclica: drug discovery services, 201811– collab using cloud-based proteome screening platform for small molecule drug development |
2018-11-26 |
| Suntory–BRAIN: food ingredients, 201811– collab €na developm natural beverage solutions with SBFE |
2018-11-26 |
| F2G Ltd–EU (govt): credit, 201811– InnovFin €24m loan from EIB to F2G Biotech GmbH for antifungals r+d |
2018-11-22 |
| Evotec–Immuneering: drug discovery software, 201811– collab AI-driven small-molecule drug discovery for hereditary metabolic diseases |
2018-11-21 |
| Quarton International–Cowen: investment, 201811–201901 acquisition of Quarton by Cowen |
2018-11-20 |
| Inflazome–Forbion: investment, 201811 financing round Series B totalling €40m incl new + lead investor Forbion Capital Partners |
2018-11-19 |
| Inflazome–Fountain Healthcare Partners: investment, 201811 financing round Series B totalling €40m incl existing + co-investor FHP |
2018-11-19 |
| Inflazome–Longitude Capital: investment, 201811 financing round Series B totalling €40m incl new + co-investor Longitude Capital |
2018-11-19 |
| Inflazome–Novartis: investment, 201811 financing round Series B totalling €40m incl existing + co-investor Novartis Venture Fund |
2018-11-19 |
| Inflazome–SEVERAL: investment, 201811 financing round Series B €40m from Forbion + Longitude Capital + NVF + Fountain Healthcare Partners |
2018-11-19 |
| Lonza–Chaim Sheba Medical Center: cell therapy manufacturing technology, 201811 collab existent to evaluate + test Cocoon technology |
2018-11-19 |
| Roche–Immunocore: ImmTAC technology, 201811– collab expansion co-developm of IMC-C103C with $100m upfront/near-term with Genentech |
2018-11-19 |
| Noxxon–SEVERAL: investment, 201811 capital increase €6.21m incl €4.4m from Acuitas Capital LLC |
2018-11-16 |
| Boehringer–Epizyme: small-molecule cancer drugs, 201811– collab strategic ww to develop inhibitors toward two epigenetic targets |
2018-11-15 |
| Cadent Therapeutics–Access Industries: investment, 201811 financing round Series B totalling $40m incl co-investor Access Industries |
2018-11-15 |
| Cadent Therapeutics–Atlas Venture: investment, 201811 financing round Series B totalling $40m incl co-lead investor Atlas Venture |
2018-11-15 |
| Cadent Therapeutics–Clal Industries: investment, 201811 financing round Series B totalling $40m incl co-investor Clal Biotechnology Industries |
2018-11-15 |
| Cadent Therapeutics–Cowen: investment, 201811 financing round Series B totalling $40m incl co-lead investor Cowen Healthcare Investments |
2018-11-15 |
| Cadent Therapeutics–Novartis: investment, 201811 financing round Series B totalling $40m incl co-investor Novartis Institutes for Biomedical Research |
2018-11-15 |
| Cadent Therapeutics–Qiming: investment, 201811 financing round Series B totalling $40m incl co-investor Qiming Venture Partners |
2018-11-15 |
| Cadent Therapeutics–SEVERAL: investment, 201811 financing round Series B $40m co-led by Cowen Healthcare Investments + Atlas Venture |
2018-11-15 |
| I-Mab–MorphoSys: antibody cancer drug, 201811– license excl Greater China + KR for MOR210 with $3.5m upfront + $101.5m milestones + royalties |
2018-11-15 |
| Alicona–Bruker: investment, 201811–201812 acquisition €na of Alicona Imaging GmbH by Bruker |
2018-11-14 |
| Virion Biotherapeutics–Trophic Communications: public relations, 201811 service existent by Trophic |
2018-11-14 |
| Roivant–SEVERAL: investment, 201811 financing round $200m led by new investors NovaQuest Capital Management + RTW Investments |
2018-11-13 |
| Aimmune Therapeutics–Nestlé: investment, 201811 equity investment $98m w 3.24m shares at $30.27/share by Nestlé Health Science brings stake to 19% |
2018-11-12 |
| Amal Therapeutics–SEVERAL: investment, 201811 financing round Series B 2nd + final closing €21.2m co-led by BIVF + BioMedPartners + Helsinn |
2018-11-12 |
| CRISPR Therapeutics–MaxCyte: gene transfer technology, 201811– license commercial to use Flow Electroporation techn for CRISPR-based I-O therapies |
2018-11-09 |
| BioNTech–Univ Pennsylvania: mRNA technology, 201811– strategic research collab €na to develop mRNA vaccines for infectious disease |
2018-11-05 |
| Marinomed–SEVERAL: investment, 201811–201901 IPO €19.5m+€2.925m with 260k+39k new bearer shares at €75/share |
2018-11-05 |
| Curetis–SEVERAL: investment, 201811 private placement €8.9m net €7.3m with 4.45m new ordinary shaes at €2/share to institutional investors |
2018-11-02 |
| Omeicos–Forbion: investment, 201811 financing round Series C totalling €17m incl new + lead investor Forbion |
2018-11-02 |
| Omeicos–SEVERAL: investment, 201811 financing round Series C €17m led by new investor Forbion |
2018-11-02 |
| HBM–CMS: legal services, 201811 supply service legal advice by CMS for both lead investors HBM + Wellington of Adrenomed Series D round |
2018-11-01 |
| Q-Bioanalytic–Eurofins: investment, 201811 acquisition by Eurofins |
2018-11-01 |
| Wellington Partners–CMS: legal services, 201811 supply service legal advice by CMS for both lead investors HBM + Wellington of Adrenomed Series D |
2018-11-01 |
| Grünenthal–AstraZeneca: esomeprazole, 201810– acquisition $922m of European rights to Nexium + ww ex US+JP rights to Vimovo |
2018-10-30 |
| Noscendo–SEVERAL: investment, 201810 financing round €7-digit led by Wieland Capital + incl HTGF + three business angels |
2018-10-29 |
| Symphogen–Thermo Fisher: mass spectrometer, 201810 supply Q Exactive Plus Orbitrap LC-MS/MS with BioPharma Option for biopharma QC |
2018-10-29 |
| Themis Bioscience–SEVERAL: investment, 201810– IPO €35m to €55.3m on Euronext Amsterdam POSTPONED 11/18 |
2018-10-29 |
| Thermo Fisher–Symphogen: mass spectrometry, 201810– collab developm biopharma QC workflows using Q Exactive Plus Orbitrap LC-MS/MS system |
2018-10-29 |
| Galecto–BPCE: investment, 201810 financing round Series C totalling €79m incl new + co-investor Seventure Partners |
2018-10-26 |
| Galecto–OrbiMed: investment, 201810 financing round Series C totalling $79m incl new + co-lead investor OrbiMed |
2018-10-26 |
| Galecto–SEVERAL: investment, 201810 financing round Series C €79m co-led by Ysios Capital + OrbiMed |
2018-10-26 |
| Galecto–Ysios Capital: investment, 201810 financing round Series C totalling $79m incl new + co-lead investor Ysios Capital |
2018-10-26 |
| BASF–MIT: CRISPR technology, 201810– license ww non-excl to CRISPR-Cpf1 technology from Broad Institute for agriculture + industrial microbiology |
2018-10-24 |
| Novartis–Philips: digital health, 201810– collab developm of SMART Suite by Alcon for cataract surgery on HealthSuite digital platform |
2018-10-23 |
| Genome Biologics (DE)–EU (govt): grant, 201810 Horizon 2020 Phase 2 Grant €2.42m |
2018-10-22 |
| VTU–KonValue: investment, 201810 acquisition of VTU Technology by KonValue Group from VTU Holding GmbH + renaming as Validogen GmbH |
2018-10-22 |
| Endocyte–Novartis: investment, 201810–201812 acquisition $2.1b in cash of Endocyte by Novartis |
2018-10-18 |
| JSR Corp–Berkeley Lights: cell line development, 201810– collab integrating SUREtechnology of Selexis with Beacon platform of BLI |
2018-10-18 |
| Kumovis–Ffilipa Venture Capital: investment, 201810 seed financing round totalling 7-digit € incl family office |
2018-10-17 |
| Kumovis–High-Tech Gründerfonds: investment, 201810 seed financing round totalling 7-digit € incl investor HTGF |
2018-10-17 |
| Kumovis–SEVERAL: investment, 201810 seed financing round 7-digit € from HTGF + Ffilipa Venture Capital |
2018-10-17 |
| Oncgnostics–Thuringia (govt): investment, 201810 additional investment of €750k from bm|t + private investors |
2018-10-17 |
| Genedata–AstraZeneca: bioinformatics, 2018 collab existent development of Genedata Imagence s/w for HCS image analysis |
2018-10-16 |
| Quantum Analytics–Bruker: analytical instruments, 201810– distribution of S2 Puma + S2 Polar + D2 Phaser analysers in the US by Quantum Analytics |
2018-10-16 |
| Warp Drive Bio–Revolution Medicines: investment, 201810 acquisition of Warp Drive Bio by Revolution Medicines |
2018-10-16 |
| LaVision BioTec–Miltenyi Biotec: investment, 201810 acquisition of LaVision BioTec GmbH by Miltenyi |
2018-10-12 |
| Gotham Therapeutics–Alexandria Real Estate: investment, 201810 financing round Series A totalling $54m incl co-investor Alexandria Venture Investments |
2018-10-10 |
| Gotham Therapeutics–Celgene: investment, 201810 financing round Series A totalling $54m incl co-investor Celgene Corp |
2018-10-10 |
| Gotham Therapeutics–Forbion: investment, 201810 financing round Series A totalling $54m incl $15m from co-lead investor Forbion IV Fund |
2018-10-10 |
| Gotham Therapeutics–GSK: investment, 201810 financing round Series A totalling $54m incl co-lead investor SR One |
2018-10-10 |
| Gotham Therapeutics–MacDougall Biomedical Communications: public relations, 201810 service existent by MacDougall |
2018-10-10 |
| Gotham Therapeutics–SEVERAL: investment, 201810 financing round Series A $54m co-led by Versant Ventures + Forbion + SR One |
2018-10-10 |
| Gotham Therapeutics–Versant Ventures: investment, 201810 financing round Series A totalling $54m incl founding + co-lead investor Versant Ventures |
2018-10-10 |
| SmartDyeLivery–PERSON: investment, 201810 financing round from bm|t + business angel from Munich |
2018-10-10 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 ... 13 14 15 ... 30 31 32 
Date![Picture [iito] Männer Ballett 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-maenner-ballett.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
